BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 1730810)

  • 1. Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins.
    de Ziegler D; Bergeron C; Cornel C; Medalie DA; Massai MR; Milgrom E; Frydman R; Bouchard P
    J Clin Endocrinol Metab; 1992 Feb; 74(2):322-31. PubMed ID: 1730810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle.
    Soules MR; McLachlan RI; Ek M; Dahl KD; Cohen NL; Bremner WJ
    J Clin Endocrinol Metab; 1989 Oct; 69(4):804-12. PubMed ID: 2506214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transvaginal administration of progesterone.
    Fanchin R; De Ziegler D; Bergeron C; Righini C; Torrisi C; Frydman R
    Obstet Gynecol; 1997 Sep; 90(3):396-401. PubMed ID: 9277651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular fluid treatment during the follicular versus luteal phase of the menstrual cycle: effects on corpus luteum function.
    Stouffer RL; Hodgen GD; Ottobre AC; Christian CD
    J Clin Endocrinol Metab; 1984 Jun; 58(6):1027-33. PubMed ID: 6427256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle.
    Nippoldt TB; Reame NE; Kelch RP; Marshall JC
    J Clin Endocrinol Metab; 1989 Jul; 69(1):67-76. PubMed ID: 2499593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma endothelin and LH-RH, LH, FSH, prolactin, progesterone, 17alpha-hydroxyprogesterone, estrone, 17beta-estradiol, delta4-androstenedione, testosterone, active renin, angiotensin-II and ANP levels in blood and LH, estrone and 17beta-estradiol and pregnanediol levels in urine of normal cycling women.
    Usuki S; Kondoh K; Kubo T
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S421-7. PubMed ID: 11078439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age effects of follicle-stimulating hormone and pulsatile luteinizing hormone secretion across the menstrual cycle of premenopausal women.
    Reame NE; Kelche RP; Beitins IZ; Yu MY; Zawacki CM; Padmanabhan V
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1512-8. PubMed ID: 8636360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone serum levels and hormone receptor contents of endometria in women with normal menstrual cycles and patients bearing endometrial carcinoma.
    Spona J; Ulm R; Bieglmayer C; Husslein P
    Gynecol Obstet Invest; 1979; 10(2-3):71-80. PubMed ID: 535775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.
    Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS
    Menopause; 2009; 16(1):50-9. PubMed ID: 18978637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone stimulates luteinizing hormone secretion by acting directly on the pituitary.
    Couzinet B; Brailly S; Bouchard P; Schaison G
    J Clin Endocrinol Metab; 1992 Feb; 74(2):374-8. PubMed ID: 1730816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept.
    Fatemi HM; Bourgain C; Donoso P; Blockeel C; Papanikolaou EG; Popovic-Todorovic B; Devroey P
    Hum Reprod; 2007 May; 22(5):1260-3. PubMed ID: 17227809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
    Couzinet B; Young J; Brailly S; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women.
    Sherman BM; Chapler FK; Crickard K; Wycoff D
    J Clin Invest; 1979 Aug; 64(2):398-404. PubMed ID: 110834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium.
    Swahn ML; Bygdeman M; Cekan S; Xing S; Masironi B; Johannisson E
    Hum Reprod; 1990 May; 5(4):402-8. PubMed ID: 2113927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of luteal phase estrogen antagonism on endometrial development and luteal function in women.
    Fritz MA; Westfahl PK; Graham RL
    J Clin Endocrinol Metab; 1987 Nov; 65(5):1006-13. PubMed ID: 3667871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificially induced menstrual cycle with natural estradiol and progesterone.
    Hung TT; Ribas D; Tsuiki A; Preyer J; Slackman R; Davidson OW
    Fertil Steril; 1989 Jun; 51(6):968-71. PubMed ID: 2498134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.